Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Biosimilars On The Horizon: How Much Will FDA Look To The East?

This article was originally published in The Pink Sheet Daily

Executive Summary

Europe's pathway for follow-on biologics has selling points for both brand and generic firms, but FDA will chart its own course - even as it mulls accepting European data.

You may also be interested in...



Practice Makes Good: FDA, EMA Focus On CROs As GCP Info Sharing Improves

FDA and EMA need more time working together before they can rely on each other’s Good Clinical Practice inspection findings, a recent joint report concludes.

Practice Makes Good: FDA, EMA Focus On CROs As GCP Info Sharing Improves

FDA and EMA need more time working together before they can rely on each other’s Good Clinical Practice inspection findings, a recent joint report concludes.

Biosimilar Guidance: Brands Try Again For A Pre-Approval Requirement

Trade associations representing largely brand manufacturers in the U.S. and Europe want FDA to release guidance on biosimilars before approving any applications, even though the law was written so the agency does not have to wait for guidance to conduct reviews.

Related Content

Topics

UsernamePublicRestriction

Register

LL035386

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel